VigenCell, a company specializing in immune cell therapy, is moving toward early commercialization after presenting significant results in Phase 2 ...
Granulocyte colony-stimulating factor to be started on day 6. Cycles to be repeated every 28 days. SMILE: Dexamethasone, methotrexate, ifosfamide, L-asparaginase and etoposide. Stage I/II ...
Extranodal NK/T-cell lymphoma(ENKTCL) and diffuse large B-cell lymphoma(DLBCL) are specific subtypes of non-Hodgkin lymphoma(NHL), which lack specific features and ...
Department of Otorhinolaryngology, Guanghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China Nasal-type extranodal NK/T-cell lymphoma (ENKTCL) is a unique ...
Epstein-Barr Virus (EBV) is an oncogenic herpesvirus linked to hematologic malignancies. EBV enters latency within host cells and can undergo lytic activation, resulting in release of infectious ...
MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that abstracts related to lacutamab health-related ...
Lacutamab is a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody that is currently in clinical trials for treatment of cutaneous T-cell lymphoma (CTCL), an orphan disease, and ...
A 73-year-old male with a history of relapsed/refractory NK T-cell lymphoma, s/p chemo and immune checkpoint inhibitors therapy. The patient now presents with new onset nephrotic syndrome and acute ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback